Our top pick for
Purple Biotech Ltd is a biotechnology business based in the US. Purple Biotech shares (PPBT) are listed on the NASDAQ and all prices are listed in US Dollars. Purple Biotech employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$4.51|
|52-week range||$3.60 - $7.25|
|50-day moving average||$4.73|
|200-day moving average||$4.69|
|Wall St. target price||$25.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.60|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.31%|
|1 month (2021-09-24)||-5.85%|
|3 months (2021-07-23)||-8.89%|
|6 months (2021-04-23)||-0.88%|
|1 year (2020-10-23)||-4.65%|
|2 years (2019-10-23)||5,994.59%|
|3 years (2018-10-23)||2,989.04%|
|5 years (2016-10-21)||1,041.77%|
|Gross profit TTM||$1 million|
|Return on assets TTM||-14.29%|
|Return on equity TTM||-16.33%|
|Market capitalisation||$80.5 million|
TTM: trailing 12 months
There are currently 1.1 million Purple Biotech shares held short by investors – that's known as Purple Biotech's "short interest". This figure is 8.4% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Purple Biotech shares can be evaluated.
Purple Biotech's "short interest ratio" (SIR) is the quantity of Purple Biotech shares currently shorted divided by the average quantity of Purple Biotech shares traded daily (recently around 113274.8496994). Purple Biotech's SIR currently stands at 9.98. In other words for every 100,000 Purple Biotech shares traded daily on the market, roughly 9980 shares are currently held short.
However Purple Biotech's short interest can also be evaluated against the total number of Purple Biotech shares, or, against the total number of tradable Purple Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Purple Biotech's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Purple Biotech shares in existence, roughly 60 shares are currently held short) or 0.0695% of the tradable shares (for every 100,000 tradable Purple Biotech shares, roughly 70 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Purple Biotech.
Find out more about how you can short Purple Biotech stock.
We're not expecting Purple Biotech to pay a dividend over the next 12 months.
Purple Biotech's shares were split on a 1:10 basis on 20 August 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Purple Biotech shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Purple Biotech shares which in turn could have impacted Purple Biotech's share price.
Over the last 12 months, Purple Biotech's shares have ranged in value from as little as $3.6 up to $7.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Biotech's is 1.9207. This would suggest that Purple Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Purple Biotech Ltd. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.